Latest News
|
|
Biologic Implants, Refined
FDA regulation, lengthy time to market and high cost of development delay the release of new Class III medical devices and Biologic therapies. Many indications exist in which Class II biomaterial therapies could provide improved outcomes while possessing a fast route to market and significantly reduced cost compared to Class III devices and Biologics. Rosivo Inc aims to develop biomaterial therapies to treat these indications.